Novocure Announces 13 Presentations and a Symposium on Tumor Treating Fields at the 70th Annual Meeting of the German Society of Neurosurgery

For the first time at this conference, a session on Tumor Treating Fields will be held

ST. HELIER, Jersey--()--Novocure (NASDAQ: NVCR) today announced 13 presentations and a symposium on Tumor Treating Fields at the 70th Annual Meeting of the German Society of Neurosurgery (DGNC) on May 12 through May 15 in Würzburg, Germany. The presentations are part of a Tumor Treating Fields session, which is a first for Novocure at this conference. Of the presentations, six are oral presentations and seven are posters. A lunch symposium will feature seven speakers on Tumor Treating Fields-related topics.

“We are pleased that Tumor Treating Fields has become a significant part of the dialogue at DGNC,” said Thomas Hefti, Vice President of Europe and Emerging Markets at Novocure. “DGNC provides a forum for the exchange of important scientific information. We look forward to sharing our science on Tumor Treating Fields and contributing to the discussion.”

Oral Presentations

(V001) The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care (TIGER – TTFields in Germany in routine clinical care). O. Bähr (Frankfurt am Main, Frankfurt), M. Glas (Essen). 8 to 8:10 a.m. CEST May 13
Studie zur Anwendung von TTFields in der klinischen Routine, bei Patientinnen und Patienten mit einem neudiagnostizierten Glioblastom in Deutschland (TIGER Studie).

(V002) Tumour-treating fields (TTF) with different settings in different glioma cell lines. G. Hatipoglu Majernik (Hannover). 8:10 to 8:20 a.m. CEST May 13
Tumortherapiefelder (TTF) mit unterschiedlichen Einstellungen in verschiedenen Gliomzelllinien

(V003) The blood brain barrier (BBB) permeability is altered by tumour treating fields (TTFields) in vitro and in vivo. E. Salvador (Würzburg). 8:20 to 8:30 a.m. CEST May 13
Die Permeabilität der Blut-Hirn-Schranke wird durch Tumor Treating Fields (TTFields) in vitro und in vivo beeinflusst

(V004) The effect of tumour treating fields on cell morphology and invasion of different cancer cells. A. Kinzel (München). 8:30 to 8:40 a.m. CEST May 13
Die Wirkung von Tumortherapiefeldern auf die Zellmorphologie und Invasion verschiedener Tumorzellen

(V005) Increased survival benefit for newly diagnosed glioblastoma patients with higher TTFields doses to the tumour bed. Z. Bomzon (Haifa, IL). 8:40 to 8:50 a.m. CEST May 13
Höhere TTFields Dosen im Tumorbett erhöhen den Überlebensvorteil bei Patienten mit einem neu diagnostizierten Glioblastom

(V006) Open-label phase 1 clinical trial testing personalised and targeted skull remodelling surgery to maximise TTFields intensity for recurrent glioblastoma – interim analysis and safety assessment (OptimalTTF-1). N. Mikic (Aarhus, DK). 8:50 – 9 a.m. CEST May 13
Open-label Phase 1 Studie zur Untersuchung einer personalisierten und zielgerichteten Remodellierungsoperation zur Maximierung der TTFields lntensität beim rezidivierenden Glioblastom - Interim-Analyse und Sicherheitsbewertung (OptimalTTF-1).

Poster Presentations

(P169) The dielectric properties of intracranial tumours. M. Proescholdt (Regensburg). 1:35 to 1:40 p.m. CEST May 14
Die bioelektrischen Eigenschaften von intrakraniellen Tumoren

(P201) Aurora kinase inhibition to enhance tumour treating fields (TTFields) efficacy in glioblastoma treatment. D. Krex (Dresden). 1:20 to 1:25 p.m. CEST May 14
Die Inhibition von Aurora-Kinasen erhöht die Effektivität einer Behandlung mit Tumor Treating Fields bei Glioblastom-Patienten

(P202) Simulation of TTFields distribution within patient-specific computational head models. Z. Bomzon (Haifa, IL) 1:25 to 1:30 p.m. CEST May 14
Simulation der TTFields Verteilung in patientenspezifischen Kopfmodellen

(P203) PriCoTTF – a phase I/II trial of tumour treating fields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. L. Lazaridis (Essen). 1:30 to 1:35 p.m. CEST May 14
PriCoTTF – eine Phase I/II Studie zu Tumortherapiefeldern vorausgehend und konkomitant zu Strahlentherapie und Temozolomid im neudiagnostizierten Glioblastom

(P205) Safety and adverse event profile of tumour treating fields in elderly patients – a post-market surveillance analysis. L. Lazaridis (Essen). 1:40 to 1:45 p.m. CEST May 14
Sicherheitsprofil von Tumortherapiefeldern (TTFields) in älteren Patienten – eine Post-Market Surveillance Analyse

(P206) Safety and adverse event profile of tumour treating fields use in the EMEA region – a real-world data analysis. L. Lazaridis (Essen) 1:45 to 1:50 p.m. CEST May 14
Sicherheitsprofil von Tumortherapiefeldern (TTFields) in der EMEA Region – Datenanalyse aus der klinischen Routine

(P207) Effect of tumour-treating fields plus chemotherapy in patients with recurrent glioblastoma. P. Spindler (Berlin) 1:50 to 1:55 p.m. CEST May 14
Der Effekt von 'tumor-treating fields' als Zugabe zu Chemotherapie in Patienten mit Glioblastom-Rezidiv

Lunch Symposium

12:15 to 1:15 p.m. CEST May 14

• D. Krex: Aurora kinase inhibition in combination with tumour treating fields (TTFields) (German)
Aurora-Kinase-Inhibierung in Kombination mit Tumortherapiefeldern (TTFields)

• L. Lazaridis: Clinical experience with the combination of TTFields with CCNU/TMZ (CeTeG) (German)
Klinische Erfahrungen mit der Kombination von TTFields und CCNU/TMZ

• C. Kramm: TTFields in pediatric patients
TTFields bei pädiatrischen Patienten

• M. Stein: Proton boost and Optune therapy in glioblastoma
Protonenboost- und Optune-Therapie beim Glioblastom

• M. Glas: TTFields and radiation – recent data and clinical developments
TTFields in Kombination mit Strahlentherapie – aktuelle Daten und klinische Entwicklungen

• M. Proescholdt: Comptune: Identification of parameters relevant for compliance in TTFields therapy
Comptune: Identifikation compliance-relevanter Parameter bei TTFields Behandlung

• A. Kessler: Experience with TTFields and meetings of patients using TTFields in Wuerzburg (German)
Erfahrungen mit TTFields und Patiententreffen von TTFields Patienten in Würzburg

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit or follow us at

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory submission and approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 28, 2019, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.


Media and Investors:
Ashley Cordova

Release Summary

Novocure announced 13 presentations and a symposium on Tumor Treating Fields at the 70th Annual Meeting of the German Society of Neurosurgery (DGNC).


Media and Investors:
Ashley Cordova